Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genmab
Originally the study was planned as Part 1A, Part 1B and Part 2. Part 1A was one arm with zalatumumab fixed dose 8 mg/kg. Part 1B was planned as zalutumumab dose-titration and Part 2 adding a comparator. The trial was prematurely closed for enrolment when patients had only been enrolled in Part 1A due to published results showing increased toxicity from induction chemotherapy without any survival benefit.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
NSCLC stage IIIA-IIIB
Performance status 0 or 1 (Zubrod or WHO Scale)
You may not be if
Evidence of metastases either in a separate lobe of the lung, or extra thoracic
Patients with high risk of radiation pneumonitis and or compromised lung function
Estimated life expectancy of less than 3 months
Prior chemotherapy for lung cancer
Prior radiotherapy to the chest
Prior surgery with curative intent for lung cancer
